Table 4.
Clinical characteristics of final analysis sample
| Height, cm | 168.4 (± 6.7) |
| Weight, kg | 72.2 (± 13.4) |
| BMI, kg/m2 | 25.4 (± 4.0) |
| Duration of T2D, years | 12.5 (± 7.8) |
| Recent HbA1c level | 7.6 (± 0.8) |
| Recent HbA1c level category | |
| ≥ 7.0%, < 7.5% | 287 (57.4%) |
| ≥ 7.5%, < 8.0% | 104 (20.8%) |
| ≥ 8.0%, < 8.5% | 56 (11.2%) |
| ≥ 8.5%, < 9.0% | 16 (3.2%) |
| ≥ 9.0% | 37 (7.4%) |
| Recent HbA1c level below or above personal target discussed with physician | |
| Below target | 42 (8.4%) |
| Above target | 444 (88.8%) |
| Don’t know | 14 (2.8%) |
| Current oral T2D treatment | |
| One medication only | 137 (27.4%) |
| Two medications only | 175 (35.0%) |
| Three or more medications | 188 (37.6%) |
| Complications related to diabetes | |
| Any complications | 45 (9.0%) |
| Kidney disease | 0 (0.0%) |
| Tingling or loss of feeling | 9 (1.8%) |
| Eye problems | 29 (5.8%) |
| Heart disease | 12 (2.4%) |
| Other complications | 1 (0.2%) |
Data are presented as n (%) or mean (± SD)
BMI body mass index, HbA1c glycated haemoglobin, n sample size, SD standard deviation, T2D type 2 diabetes